| Domain | Key finding | Quantitative detail | Evidence type | Source/date/DOI |
|---|---|---:|---|---|
| Disease definition | Foundational description of SPOP-related neurodevelopmental disorder identified two clinically distinct syndromic presentations caused by de novo SPOP missense variants | 7 affected individuals; 6 unique de novo missense variants; ascertainment from large exome cohorts including 4,749 unexplained ID cases, 1,133 developmental disorder cases, and 14,183 NDD cases | Human clinical + human functional | Sá et al., *Am J Hum Genet*, Mar 2020, doi:10.1016/j.ajhg.2020.02.001 (pqac-00000000, pqac-00000001) |
| Core phenotype | Shared phenotype across reported individuals includes intellectual disability, motor delay, speech delay, facial dysmorphism, and congenital anomalies | ID 7/7; motor delay 7/7; speech delay 7/7; facial dysmorphism 7/7; congenital anomalies 7/7 | Human clinical | Sá et al., Mar 2020, doi:10.1016/j.ajhg.2020.02.001 (pqac-00000021) |
| Variant group 1 | p.Arg121Gln and p.Asp144Asn define a microcephaly/hearing-loss group with gain-of-function behavior toward BET protein reduction | 2/7 individuals; congenital microcephaly 2/2; hearing loss 2/2 | Human clinical + human cell functional | Sá et al., Mar 2020, doi:10.1016/j.ajhg.2020.02.001 (pqac-00000000, pqac-00000006) |
| Variant group 2 | p.Thr25Ala, p.Tyr83Cys, p.Gly132Val, and recurrent p.Arg138Cys define a macrocephaly/multisystem group with dominant-negative behavior and BET protein increase | 5/7 individuals; macrocephaly/relative macrocephaly 5/5; cardiovascular abnormalities 4/4 reported; endocrine abnormalities 3/4; epilepsy 2/5; sleep disturbance 4/5; short stature/failure to thrive 2/5 | Human clinical + human cell functional | Sá et al., Mar 2020, doi:10.1016/j.ajhg.2020.02.001 (pqac-00000000, pqac-00000006) |
| Molecular mechanism in patients | Opposite functional classes converge on dysregulation of BET proteins BRD2/3/4 | Group 1 variants reduced BET protein amounts; group 2 variants increased BET protein amounts | Human cell functional | Sá et al., Mar 2020, doi:10.1016/j.ajhg.2020.02.001 (pqac-00000000, pqac-00000005, pqac-00000006) |
| Structural interpretation | Disease variants cluster in or near the substrate-recognition region of SPOP, consistent with altered substrate handling | 6 pathogenic missense alleles reported in MATH/BTB-related functional regions; recurrent p.Arg138Cys in 2 individuals | Human genetics + structural inference | Sá et al., Mar 2020, doi:10.1016/j.ajhg.2020.02.001 (pqac-00000004, pqac-00000005) |
| General SPOP biology | SPOP is the substrate adaptor of the CUL3/RBX1 E3 ligase complex; substrate binding uses MATH domain, dimerization/oligomerization uses BTB/BACK, and LLPS-like condensates can enhance ubiquitination | 374-aa protein; >33 substrates reported in review literature; BET proteins included among substrates | Authoritative review; non-disease-specific | Zhang et al., *Cancer Research*, Dec 2023, doi:10.1158/0008-5472.CAN-22-2801 (pqac-00000008, pqac-00000010); Ovalle et al., Sep 2021, doi:10.35509/01239015.717 (pqac-00000009, pqac-00000011) |
| Upstream/downstream interpretation | **Inferred:** altered substrate recognition by mutant SPOP leads to abnormal BRD2/3/4 turnover, which likely perturbs cell-cycle progression and neuronal differentiation, contributing to head-size and neurodevelopmental phenotypes | No patient neural tissue transcriptomic/proteomic readout available | Inference from human functional data + literature | Sá et al., Mar 2020 (pqac-00000002, pqac-00000005); Zhang et al., Dec 2023 (pqac-00000008) |
| Brain imaging/anatomy | Available neuroimaging evidence is limited but includes ventriculomegaly in part of the macrocephaly group | Postnatal ventriculomegaly reported in 2 individuals (individuals 3-4) | Human clinical | Sá et al., Mar 2020, doi:10.1016/j.ajhg.2020.02.001 (pqac-00000002) |
| Mouse developmental mechanism | Spop regulates Gli3 abundance and modulates Shh/Hedgehog signaling during spinal cord development; nervous-system defects occur in some loss-of-function embryos | Subset with exencephaly/spina bifida; normal D/V patterning in simple Spop mutants but severe ventralization in sensitized double/triple mutant contexts | Mouse genetics/mechanistic | Cai & Liu, *Dev Biol*, Dec 2017, doi:10.1016/j.ydbio.2017.04.002 (pqac-00000014, pqac-00000016, pqac-00000017) |
| Mouse skeletal rescue | Spop promotes skeletal development by restraining Gli3 repressor; lowering Gli3 dosage rescues Spop skeletal phenotypes | Spop-null/conditional mice show brachydactyly, osteopenia, delayed ossification; rescue demonstrated in Spop;Gli3+/− backgrounds | Mouse genetics + rescue | Cai & Liu, *PNAS*, Dec 2016, doi:10.1073/pnas.1612520114 (pqac-00000012, pqac-00000013, pqac-00000015, pqac-00000018, pqac-00000019) |
| Relevance of animal models to human NDD | **Inferred/plausible branch:** GLI3/Hedgehog dysregulation may contribute to human SPOP syndrome, but this has not been directly demonstrated in patient-derived neural tissue or patient cohorts | 0 direct patient GLI3/Hedgehog biomarker studies identified | Cross-species inference/data gap | Human study + mouse studies (pqac-00000005, pqac-00000014, pqac-00000018) |
| Recent developments (2023-2024) | Recent literature places SPOP-related disease within the broader chromatinopathy/epigene-disorder landscape and emphasizes epigenetic-state imbalance as a diagnostic concept | Review notes 154 epigenes linked to chromatinopathies overall; no SPOP-specific episignature demonstrated in retrieved evidence | 2024 review; contextual | Bukowska-Olech et al., *J Appl Genet*, Jan 2024, doi:10.1007/s13353-023-00824-1 (context available from paper search results; no disease-specific context ID extracted) |
| Diagnostics | Real-world identification is via exome/genome-based rare-disease diagnostics, typically trio analysis with de novo confirmation | All foundational SPOP variants were de novo; Sanger confirmation reported | Human clinical genomics | Sá et al., Mar 2020, doi:10.1016/j.ajhg.2020.02.001 (pqac-00000000) |
| Epidemiology | Ultra-rare Mendelian disorder; no prevalence or incidence estimates were found in retrieved authoritative sources | Prevalence: not available; incidence: not available | Data gap | No retrievable disease-specific epidemiology in available evidence (pqac-00000021, pqac-00000024) |
| Treatment/guidelines | No disease-specific pharmacologic therapy, gene therapy, or formal management guideline identified | 0 relevant clinical trials found; 0 disease-specific treatment studies found | Negative evidence / data gap | Clinical-trial searches negative; case-report literature states no follow-up guidelines established (pqac-00000023, pqac-00000024) |
| Current care implementation | Management is phenotype-driven multidisciplinary care rather than syndrome-specific therapy | Specialists explicitly suggested include neurology, cardiology, ophthalmology, and otorhinolaryngology | Case report / extrapolated standard care | Olivares-Huerta et al., *Cureus*, Apr 2026, doi:10.7759/cureus.107064 (pqac-00000023, pqac-00000024) |
| Evidence gaps | No disease-specific natural history, survival statistics, QoL studies, penetrance estimates, protective factors, environmental triggers, gene-environment interactions, single-cell/spatial omics, or episignature validation were found | 0 direct studies identified for each listed category in retrieved evidence | Data gap | Synthesized from all retrieved evidence (pqac-00000021, pqac-00000024) |


*Table: This compact table summarizes the strongest available evidence for SPOP-related neurodevelopmental disorder, spanning the founding human cohort, mechanistic variant groups, relevant SPOP biology, and model-organism studies. It also highlights major evidence gaps, including the lack of disease-specific trials or guidelines.*